Vikram Purohit
Stock Analyst at Morgan Stanley
(0.82)
# 3,924
Out of 4,984 analysts
156
Total ratings
29.51%
Success rate
-12.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Vikram Purohit
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABSI Absci | Maintains: Overweight | $6.4 → $5.89 | $2.55 | +130.98% | 3 | Aug 18, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Overweight | $75 → $80 | $75.81 | +5.53% | 9 | Aug 18, 2025 | |
| RXRX Recursion Pharmaceuticals | Assumes: Equal-Weight | $5 | $4.71 | +6.16% | 4 | Jul 3, 2025 | |
| ASND Ascendis Pharma | Upgrades: Overweight | $180 → $250 | $199.59 | +25.26% | 19 | May 5, 2025 | |
| INCY Incyte | Maintains: Equal-Weight | $69 → $65 | $84.80 | -23.35% | 24 | Mar 24, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $125 → $190 | $116.62 | +62.92% | 19 | Feb 27, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Overweight | $40 → $35 | $19.07 | +83.58% | 2 | Dec 11, 2024 | |
| FHTX Foghorn Therapeutics | Maintains: Equal-Weight | $6 → $9 | $4.80 | +87.50% | 9 | Sep 24, 2024 | |
| GMAB Genmab | Maintains: Equal-Weight | $31 | $28.08 | +10.40% | 2 | Sep 11, 2024 | |
| ABVX ABIVAX Société Anonyme | Maintains: Equal-Weight | $15 → $16 | $81.00 | -80.25% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $5.04 | +495.24% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $10 | $17.14 | -41.66% | 8 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $46 → $6 | $2.31 | +159.74% | 1 | Nov 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $42 | $9.03 | +365.12% | 8 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $38 → $41 | $48.12 | -14.80% | 12 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $120 → $40 | $21.55 | +85.66% | 7 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $13 | $2.53 | +413.83% | 1 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $38 | $19.03 | +99.68% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $24 → $20 | $11.51 | +73.76% | 5 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | $14.05 | -28.83% | 11 | Jul 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.60 | +1,275.00% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $20 | $9.87 | +102.66% | 2 | Aug 5, 2020 |
Absci
Aug 18, 2025
Maintains: Overweight
Price Target: $6.4 → $5.89
Current: $2.55
Upside: +130.98%
Halozyme Therapeutics
Aug 18, 2025
Maintains: Overweight
Price Target: $75 → $80
Current: $75.81
Upside: +5.53%
Recursion Pharmaceuticals
Jul 3, 2025
Assumes: Equal-Weight
Price Target: $5
Current: $4.71
Upside: +6.16%
Ascendis Pharma
May 5, 2025
Upgrades: Overweight
Price Target: $180 → $250
Current: $199.59
Upside: +25.26%
Incyte
Mar 24, 2025
Maintains: Equal-Weight
Price Target: $69 → $65
Current: $84.80
Upside: -23.35%
Axsome Therapeutics
Feb 27, 2025
Maintains: Overweight
Price Target: $125 → $190
Current: $116.62
Upside: +62.92%
Zenas BioPharma
Dec 11, 2024
Maintains: Overweight
Price Target: $40 → $35
Current: $19.07
Upside: +83.58%
Foghorn Therapeutics
Sep 24, 2024
Maintains: Equal-Weight
Price Target: $6 → $9
Current: $4.80
Upside: +87.50%
Genmab
Sep 11, 2024
Maintains: Equal-Weight
Price Target: $31
Current: $28.08
Upside: +10.40%
ABIVAX Société Anonyme
Apr 11, 2024
Maintains: Equal-Weight
Price Target: $15 → $16
Current: $81.00
Upside: -80.25%
Apr 1, 2024
Initiates: Overweight
Price Target: $30
Current: $5.04
Upside: +495.24%
Nov 13, 2023
Maintains: Overweight
Price Target: $45 → $10
Current: $17.14
Upside: -41.66%
Nov 7, 2023
Downgrades: Equal-Weight
Price Target: $46 → $6
Current: $2.31
Upside: +159.74%
Aug 29, 2023
Maintains: Overweight
Price Target: $43 → $42
Current: $9.03
Upside: +365.12%
Dec 19, 2022
Maintains: Equal-Weight
Price Target: $38 → $41
Current: $48.12
Upside: -14.80%
Dec 12, 2022
Maintains: Equal-Weight
Price Target: $120 → $40
Current: $21.55
Upside: +85.66%
Nov 10, 2022
Initiates: Equal-Weight
Price Target: $13
Current: $2.53
Upside: +413.83%
Nov 4, 2022
Maintains: Equal-Weight
Price Target: $39 → $38
Current: $19.03
Upside: +99.68%
Aug 24, 2022
Maintains: Equal-Weight
Price Target: $24 → $20
Current: $11.51
Upside: +73.76%
Jul 25, 2022
Maintains: Underweight
Price Target: $11 → $10
Current: $14.05
Upside: -28.83%
Aug 10, 2021
Initiates: Overweight
Price Target: $22
Current: $1.60
Upside: +1,275.00%
Aug 5, 2020
Maintains: Equal-Weight
Price Target: $40 → $20
Current: $9.87
Upside: +102.66%